ACT FOR ULTRA RARE

Lobbying client · District of Columbia · filed 2026 to 2026

Advocacy for ultra rare disease

$75,000 Reported spend

3 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 3 filings. Everything on this page is grouped by the client's LDA id (72610), not by name.

Firms hired 1

AVIVA STRATEGIES (FKA MGB CONSULTING) $75,000 3 filings

Reported by year 1 year

2026 $75,000 3 filings

Issues lobbied 1

Health Issues 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 1

HOUSE OF REPRESENTATIVES 2

Recent filings 3 total

Q2

AVIVA STRATEGIES (FKA MGB CONSULTING)

2nd Quarter (Apr 1 - June 30) 2026 · House · $37,500 income · posted Jul 17, 2026

View → Q1

AVIVA STRATEGIES (FKA MGB CONSULTING)

1st Quarter (Jan 1 - Mar 31) 2026 · House · $37,500 income · posted Apr 20, 2026

View → RR

AVIVA STRATEGIES (FKA MGB CONSULTING)

1st Quarter (Jan 1 - Mar 31) 2026 · posted Apr 17, 2026

View →

Affiliated organisations 2

CHIESI USA United States of America named on 1 filing
ULTRAGENYX United States of America named on 1 filing

Section 6 of the LD-2: organisations that contribute to or take part in this client's lobbying.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.